Removing a requirement that rituximab be approved by the federal Food and Drug Administration to be subject to a requirement on certain insurers, nonprofit health service plans, and health maintenance organizations to provide coverage for the treatment of certain pediatric autoimmune neuropsychiatric disorders; etc.
Bill File Type: Regular
Effective Date(s): January 1, 2023
HistoryToggle History Dropdown
File CodeToggle Filecode Dropdown
SubjectsToggle Subjects Dropdown
StatutesToggle Statutes Dropdown
Last Updated: 5/19/2022 1:49 PM